Tuesday, November 28, 2023
Inflammatory joint diseases, such as psoriatic arthritis (PsA) and rheumatoid arthritis (RA), are associated with severe disability and increased mortality. Over the last several years, new immunotherapeutic targets have been recognized. Progress in treatment using biologic disease-modifying antirheumatic drugs (DMARDs) targeting interleukin (IL)-17 and, most recently, JAK inhibitors has improved the management of these diseases and made clinical remission a realistic target. This curriculum aims to educate clinicians about the latest clinical evidence and best practices regarding the treatment of patients with inflammatory joint diseases.
Supported by an independent educational sponsorship from
Steering Committee Chair
Professor
University of Glasgow
Glasgow, Scotland, United Kingdom
Professor of Medicine
Department of Rheumatology and Clinical Immunology
Charité - University Medicine
Berlin, Germany
Clinician Scientist
University of Oxford
Oxford, United Kingdom
Professor of Medicine
University of Toronto
Toronto, Ontario, Canada
Clinical Professor
University of Washington School of Medicine
Director of Rheumatology Research
Swedish Medical Center
Seattle, Washington, United States
Professor
Oxford University Hospital
Oxford, United Kingdom
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Celgene Corporation; Eli Lilly and Company; GlaxoSmithKline; Janssen Pharmaceuticals; Leo Pharma; Novartis Pharmaceuticals Corporation; UCB Pharma, Inc.
Received grants for clinical research from: Celgene Corporation; Janssen Pharmaceuticals; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
TBD
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Galapagos NV; Janssen Pharmaceuticals; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Prothena Corp; UCB Pharma, Inc.
Received grants for clinical research from: AbbVie Inc.; Celgene Corporation; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Galapagos NV.; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; UCB Pharma, Inc.
Served as a speaker or a member of a speakers bureau for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Genentech, Inc.; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; UCB Pharma, Inc.
Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; Celgene Corporation; Eli Lilly and Company; Janssen Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Sun Pharmaceutical Industries Ltd.; UCB Pharma, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AbbVie Inc.; Biogen; Eli Lilly and Company; Galapagos NV; GlaxoSmithKline; Janssen Pharmaceuticals; Nordic Pharma; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche Holdings AG; Sandoz; UCB Pharma, Inc.
Received grants for clinical research from: Celgene Corporation; Eli Lilly and Company; Galapagos NV; UCB Pharma, Inc.